Press Releases

2012

April 2012 - Aqix Ltd becomes SME member of COPE (Consortium on Organ Preservation in Europe) whereby investigations involving AQIX® RS-I as a base physiological solution will be used to maintain the functionality of human donor organs at normal body temperatures as a means of providing better preservation of donor grafts for transplantation. This FP7-HEALTH-2012-INNOVATION-1 is sponsored by the European Commision and involves both science and clinical institutions intimately involved with advancements in transplant technology and is tenable at various centres for 54 months commencing January 1st, 2013. Aqix Ltd is responsible for the GMP manufacture of AQIX® RS-I  in a 'ready-to-use' IV bag or bottle format during this period.

2011

June 2011 - Aqix Ltd wins a competition award of £60k as part of the Technology Strategy Board Grant for Research and Development to fund the pilot investigation of AQIX® RS-I in the only UK survival model of cardiopulmonary bypass in collaboration with the University of Bristol.

2010

July 2010 - Aqix Ltd wins a competition award of £330k as part of the Technology Strategy Board Regenerative Medicine Programme for Developing Therapeutics to fund the further development of AQIX® RS-I and extended research into organ transplant application in collaboration with the University of Newcastle.

2009

November 2009 - Aqix Ltd wins a competition award of £100k as part of the Technology Strategy Board Regenerative Medicine feasibility studies to fund the development of AQIX® RS-I.

2008

February 2008 - DrugMode, Denmark. AQIX® RS-I adopted as pre-incubation medium in data base for isolation of human hepatocytes used in drug throughput bioassay procedures.

March 2008 - Cureline Inc., USA/USSR. Aqix Ltd enters a co-marketing agreement with Cureline Inc. a custom tissue acquisition provider with an emphasis on custom human tissue acquisition for target validation, drug discovery, diagnostic and clinical development.

September 2008 - Res-Del® Ltd, New Zealand. AQIX® RS-I adopted as perfusate solution in the data base for perfusion of animal and human biopsies using the patented horizontal Res-Del® 591 Organ Perfusion/Perifusion Bath System.

2007

December 2007- Biopta, UK. AQIX® RS-I adopted as data base for storage, transportation and normothermic perfusion of human cadaver tissue biopsies used in drug bioassay procedures

2006

March 2006 – Bowman Research/Organ Recovery Systems, Belgium/USA. AQIX® RS-I adopted as data base for Ex Vivo perfusion of KPS-1 human cadaver organs used in drug bioassay procedures.